Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incannex Healthcare Inc. - Common Stock
(NQ:
IXHL
)
1.760
-0.010 (-0.56%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incannex Healthcare Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
June 01, 2023
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.
Via
Talk Markets
Incannex welcomes world-leading psychedelics experts to advisory board
June 01, 2023
Incannex welcomes world-leading psychedelics experts to advisory board
Via
News Direct
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
May 23, 2023
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...
Via
Benzinga
Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary
May 16, 2023
Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd.
Via
Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
May 08, 2023
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via
Benzinga
Why Incannex Healthcare Shares Are Gaining Today
March 15, 2023
Via
Benzinga
Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
March 14, 2023
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.
Via
Talk Markets
Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic
May 05, 2023
Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne.
Via
Benzinga
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
May 03, 2023
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Via
News Direct
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
April 25, 2023
Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual...
Via
Benzinga
Largest Psychedelic Stocks -3.4% In March
April 02, 2023
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts.
Via
Talk Markets
Cannabis Category Performances Ranged From +8.6% To -7.0% This Week
March 25, 2023
The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example.
Via
Talk Markets
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
March 20, 2023
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered
Via
Benzinga
Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary
March 17, 2023
Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership...
Via
Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
March 15, 2023
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.
Via
Benzinga
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 15, 2023
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 15, 2023
Via
Benzinga
All 5 Cannabis Categories Down Last Week; Only 1 Is UP YTD
March 12, 2023
The 5 categories in the cannabis sector perform quite differently from each other. Only 1 is up YTD.
Via
Talk Markets
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...
Via
Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
March 06, 2023
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Via
Benzinga
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
March 03, 2023
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Via
News Direct
Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials
March 03, 2023
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has...
Via
Benzinga
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
February 28, 2023
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
Via
News Direct
Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
February 28, 2023
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 25, 2023
Via
Benzinga
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
January 25, 2023
Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a...
Via
Benzinga
Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results
January 18, 2023
Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.